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A B S T R A C T
Background: The objective of this study is to assess the current literature on the effectiveness of fibrin glue on
survival of skin grafts. Fibrin glue is a possible alternative to secure skin grafts instead of traditional methods (i.e.
sutures or staples).
Methods: Data Sources: MEDLINE, Scopus, Embase, Informit, CINAHL and the Cochrane Central Register of
Controlled Trials, no limit on the earliest date of publication.
Study eligibility criteria: Randomised, non-randomised controlled trials and cohort studies.
Participants: and Interventions: Participants were patients with skin grafting/skin transplantation. The inter-
vention was fibrin glue in any form (bovine, human pooled plasma or autologous) and comparator any form of
affixing skin grafts (e.g. sutures or staples).
Study Appraisal and Synthesis Methods: Studies were appraised using the Cochrane risk of bias tool and
assessed for clinical heterogeneity. Effect sizes were calculated and illustrated with forest plots.
Results: 190 publications were narrowed to 15 relevant publications, of which eight were pooled in meta-ana-
lysis. The outcomes examined were: graft survival by percentage; graft survival reported as events; post-op-
erative incidence of haematoma or seroma; pain reported after dressing changes via a visual analogue scale;
length of stay in days (Glass's delta 2 was 0.48 95% CI 0.09, 0.97); and surgical time in minutes. Only length of
stay showed a difference between groups and it favoured fibrin glue.
Conclusions: While there may be benefits to the use of fibrin glue in skin graft patients, it is difficult to conclude




Fibrin glue, composed of thrombin, factor XIII, calcium and fi-
brinogen, was initially developed for use as a haemostatic agent. When
introduced to a wound it mimics the final events in the clotting cascade,
turning fibrinogen into fibrin [1–3]. When applied between the skin
graft and the wound it produces a biological adherent over the entire
surface of the graft, as opposed to the traditional method of fixation (i.e.
sutures or staples) where adherence is only secured at the edges of the
graft. Originally the source of fibrin was centrifuged patient plasma.
Now commercial preparations of high concentrations of fibrin are now
available and can be used as adhesives [4]. There are a few main
subtypes of fibrin glue used in practice: autologous glue, where the
patient's own plasma is processed to maintain only the fibrin rich as-
pects; homologous glue where plasma is taken from a number of vo-
lunteers and processed to become fibrin rich; and bovine glue where
fibrin proteins are extracted from bovine plasma [5–7].
Fibrin glue has been investigated for use in skin grafts for burns and
compared to staples/sutures in terms of wound closure [8]. Skin graft
survival is dependent on vascularisation of the graft which usually
begins after 2–3 days. During this period poor adherence or haema-
toma/seroma formation can disrupt further vascularisation and lead to
graft failure [9]. Specifically, because fibrin glue adheres the entire
surface of the graft to the wound, it can reduce the formation of hae-
matoma or seroma immediately post operatively [9]. Studies have also
shown less requirement for dressings to ensure close adherence of the
graft, better haemostasis and less contraction of scar tissue for various
uses of skin grafts [7,10,11]. Issues with the graft recipient site such as
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poor vascularity, infection and inflammation can also lead to graft
failure [9]. Fibrin glue has been investigated for use in other difficult to
graft situations such as infected sites and over joint surfaces [12–17]. It
is possible that fibrin glue can increase graft survival in patients who
have vascular issues as it has been shown that increased fibrin decreases
likelihood of graft failure and can induce angiogenesis [18].
Queensland, Australia has the highest rate of skin cancer in the
world [19]. Moreover, the Australian Institute of Health and Welfare,
also notes that melanoma related hospitalisations have risen 63% in the
last decade [19]. Admitted patients are usually those needing large
excisions to obtain adequate surgical margins and may require skin
grafts to close their defects [20]. Patients with skin cancer are more
Fig. 1. PRISMA flow diagram.
Table 1a
Summary of paper characteristics.
# Name Year Random
Allocation
Total N N glue N control Diagnosis Age (range: x to x or
mean ± SD)
Sex (ratio of Male to
Female)
Country
1 Boccara [39] 2017 N 28 28 6 Burns NI 4.5 France
2 Boeckx [40] 1992 N 27 15 12 Burns 8 to 57 NI Belgium
3 Burton [29] 2019 Y 17 NI NI Burns 39 (Fibrin) 43 (Control) 0.7 USA
4 Dahlstrom [30] 1992 Y 7 7 7 Ulcers NI NI Denmark
5 Danielsen [31] 2008 Y 20 10 10 Ulcers 44 to 86 0.8 Denmark
6 Erba [32] 2010 Y 10 5 5 Ulcers 55 ± 11 9 Switzerland
7 Foster [28] 2008 Y 138 138 138 Burns 1 to 62 1.9 USA
8 Gibran [27] 2007 Y 40 40 40 Burns 6.2 to 54.6 2.6 USA
9 Greenhalgh [33] 1999 Y 47 47 47 Burns 7 to 78 2.9 USA
10 Han [37] 2016 N 55 25 30 Trauma, Burns NI NI South Korea
11 Healy [34] 2013 Y 40 20 20 Trauma, Skin
Cancer
60 1.0 UK
12 McGill [38] 1997 N 95 34 61 Burns 10 ± 3.1 (Fibrin) 9.7 ± 3.9
(Control)
1.3 USA
13 Moraes [35] 1998 Y 14 14 14 Skin Cancer 30 to 90 NI Brazil
14 Reddy [41] 2017 N 16 8 8 Trauma, Burns,
Ulcers
13 to 52 1.0 India
15 Youngmin [36] 2018 N 40 20 20 Burns 44 ± 15.2 5.7 South Korea
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likely to be elderly and with comorbidities and therefore carry an in-
creased risk of graft failure, as opposed to burns patients where children
are highly represented [21,22].
Sixty-five review papers were found, however only two of these
were systematic and both only examined burns patients [23,24]. There
is a need for a review that is much broader in scope, and has been
conducted more extensively than what is currently published. Given
this context, the aim of this review is to broadly study the literature
around fibrin glue and its potential applicability to skin cancer patients.
1.2. Objectives
The objective for this systematic review is to ascertain to what ex-
tent the current published literature supports the use of fibrin glue in
skin grafts, and the quality of that literature. This review will also
question whether this literature can be applied to the population of
patients requiring grafting for skin cancer, as published results suggest
that much of the literature relating to skin grafts pertains specifically to
burns patients.
2. Methods
2.1. Protocol and registration
The systematic review protocol was developed in accordance with
PRISMA guidelines and the study protocol was published prospectively
in the PROSPERO international prospective register of systematic re-
views (CRD42018088263).
2.2. Eligibility criteria
Prospective studies, including randomised controlled trials, con-
trolled trials and cohort studies with a comparator group were eligible.
The eligibility was extended beyond randomised controlled trials due to
the small number of published papers. Retrospective studies, case re-
ports or case series were not included in this search. Participants in-
cluded patients who had undergone skin grafting, also termed skin
transplantation. The intervention of interest was fibrin glue in any form
(bovine, human pooled plasma or autologous) and the comparator was
any typical form of affixing skin grafts (e.g. sutures or staples). The
major outcome of interest was graft survival. Secondary outcomes were
rates of haematoma/seroma, postoperative pain, length of stay and
operative time.
2.3. Information and sources
A search of the English language literature was conducted using the
databases MEDLINE, Scopus, Embase, Informit, CINAHL and the
Cochrane Central Register of Controlled Trials with no limit on the
earliest date of publication. This was last conducted on October 8,
2019.
2.4. Search strategy
The aim was to find papers about both fibrin glue and skin grafts or
flaps. The first search term of fibrin glue was mapped to the MESH term
“Fibrin Tissue Adhesive” and other synonyms such as “Fibrin Glue”,
“Fibrin Sealant”, “Tissue Adhesive” and brand names such as “ARTISS”,
“Tisseel” and “Beriplast” were included. These terms were all searched
using the OR Boolean operator. The second term mapped to the MESH
heading of “Skin Transplantation” and synonyms such as
“Dermatoplasty” and “Skin Graft” were included using the OR operator.
These searches were then combined using the AND operator.
2.5. Study selection
Studies were screened by title and abstract and subsequently by full
text review for adherence to the eligibility criteria. Studies excluded
were those using animal or in vitro models and those in which the in-
tervention was not fibrin glue. Abstracts and unpublished studies were
included.
2.6. Data collection process
Two investigators experienced in systematic reviews reviewed pa-
pers for inclusion and extracted data. Any disagreements were referred
to a third researcher.
2.7. Data items
The eight papers included had data extracted including study de-
sign; study duration; sequence generation; allocation; sequence con-
cealment; blinding; other bias; total number of participants; setting;
diagnosis; age; sex; country; co-morbidity (in particular vascular co-
morbidity); total number of intervention groups; intervention (fibrin
glue); type of glue (autologous/bovine); alternative intervention (su-
tures/staples); graft survival; haematoma/seroma/complication; pain;
operative time; aesthetic outcome; number of participants in each in-
tervention group; sample size; missing participants; statistical means
and standard deviations for outcomes; funding source; study
Table 1b
Summary of paper characteristics.
# Name Co-morbidity Type of graft (Split thickness STSG, Full Thickness
FTSG)
Type of Fibrin Glue Control
1 Boccara NI STSG Bovine (ARTISS) Staples
2 Boeckx NI STSG Bovine (Tisseel) Sutures (Vicryl)
3 Burton Excluded STSG Not Specified Staples
4 Dahlstrom NI STSG Autologous Dressing Only
5 Danielsen Included STSG Autologous (Vivostat) Staples
6 Erba NI Fasciocutaneous Thigh Flap Bovine (Tisseel) Sutures (monocryl)
7 Foster NI STSG Bovine (ARTISS) Staples
8 Gibran Excluded STSG Bovine (ARTISS) Staples
9 Greenhalgh NI STSG Bovine (ARTISS) Staples
10 Han NI STSG Human (Greenplast) Sutures (silk)
11 Healy Included STSG Bovine (Tisseel) Dressing Only
12 McGill Excluded STSG Human derived fibrin sealant (Baxter) Staples
13 Moraes NI FTSG Autologous (Glycine Precipitation Technique) No Grafting
14 Reddy NI STSG Pooled human plasma (EVICEL) Suture or Staples
15 Youngmin Excluded STSG Human (Greenplast Q; Green Cross Corporation, Yongin, South
Korea)
Staples
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conclusions; miscellaneous comments.
2.8. Risk of bias in individual studies
Risk of bias was assessed using the Cochrane risk of bias tool. Bias
was assessed in the domains of selection, performance, detection, at-
trition, reporting and other sources of bias. A funnel plot was planned if
ten or more studies were pooled in meta-analysis.
2.9. Risk of bias across studies
Publication bias is likely in that studies which did not show any
benefit of the fibrin glue may not have been published nor have been
registered on a clinical trial database.
2.10. Meta-analysis
Meta-analysis was conducted in STATA SE16 [25]. The studies
which were meta-analysed were only those using staples or sutures as a
comparator as these are the same method of direct fixation around the
edge of the graft. Outcomes were reported in literature as mean and
standard deviation, number of events over total sample or median and
range. Estimates of mean and standard deviation were calculated from
medians and ranges as per methodology published in BioMed Central
for the purposes of meta-analysis [26]. Authors were contacted for data
which was not included in publication which could be used to calculate
effect estimates. Further information was provided by authors for two
papers [27,28]. A random effects model was used for all cumulative
effect calculations. Glass's delta 2 with 95% confidence interval for
continuous outcome variables and log odds ratio for binary outcomes
were calculated as effect sizes. This was also illustrated in forest plots.
3. Results
3.1. Study selection
A total of 1090 publications were initially found. Duplicates were
removed and 763 records were screened by title and abstract (Fig. 1).
Records were excluded if they were not relevant to the topic and
common reasons for exclusion were papers studying tissue engineering
where the intervention was not the application of fibrin glue, or papers
studying animal models of skin grafts. After the initial review, papers
were also excluded due to study type (i.e. case reports and review pa-
pers). Fifteen studies were found to meet the criteria outlines in the
objectives. Twenty-seven papers were excluded based on language,
however English translations of abstracts were available for these and
none appeared to meet the inclusion criteria.
3.2. Study characteristics
Nine of the studies included were randomised controlled trials
[27–35], one was a prospective cohort study [36] and the remainder
were controlled trials (Table 1a–c). Studies were published between
1992 and 2019. Only three studies had a total number of participants
greater than 50 [28,37,38], and only two studies included skin cancer
patients in their population [34,35]. Therefore, 16 of the 594 total
patients studied had skin cancer. Many studies included paediatric
patients and the overall gender ratio was skewed toward males. The
United States of America published five studies on this topic which was
more than any other country [27–29,33,38].
Only two studies included patients who had vascular comorbidities,
one of them being Healy et al. which also included skin cancer patients
[31,34]. One study examined fasciocutaenous thigh flaps rather than
skin grafts [32], one was full thickness skin grafts [35] with the re-
mainder being split thickness skin grafts. Seven papers examined bo-
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Fig. 2a. Forest plot of graft survival (%).
Fig. 2b. Forest Plot of Graft Survival reported by event.
Fig. 2c. Forest plot of haematoma seroma events.
Fig. 2d. Forest Plot of reported pain after dressing changes (Visual Analog Scale).
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[27,28,32–34,39,40]. Eleven papers compared to sutures or staples for
the control group [27–29,31,33,36,39,41]. Five studies were funded by
manufacturers of the product studied [27,28,31,33,38].
3.3. Meta-analysis
As detailed in Table 1c, the outcomes examined were quite variable
in each paper, thus six common outcomes were used for meta-analysis
(Fig. 2a–f). These are: graft survival by percentage; graft survival
Fig. 2e. Forest plot of length of stay (Days).
Fig. 2f. Forest plot of surgery time (minutes).
Fig. 3. Risk of Bias Assessment for studies included in the meta-analysis.
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reported as events; post-operative incidence of haematoma or seroma;
pain reported after dressing changes via a visual analog scale; length of
stay in days; and surgical time in minutes. A difference between groups
was only seen for length of stay in days (Fig. 2e). A funnel plot was not
completed as there was not a sufficient number of studies. Only graft
survival reported by event had a heterogeneity less than 50%. All stu-
dies included in the meta-analysis posed an intermediate risk of bias,
primarily due to randomisation and selection of reported results
(Fig. 3).
4. Discussion
4.1. Summary of evidence
The current published literature does not conclusively demonstrate
that fibrin glue is superior to a comparator. The reasons for this might
be that fibrin glue is not superior or that this has so far not yet been
proven due to only a few small studies available. A large sample size is
required since the overall percentage of graft take in both groups being
quite high, perhaps due to the exclusion of patients with comorbidities
who predispose to lower graft survival, and the existing studies are
therefore most likely underpowered.
Most notably, a few papers demonstrated decreased pain after
dressing change for patients with fibrin glue used (Fig. 2d). Two articles
which did use pain as an endpoint were unable to be included because
instead of reporting pain scores, usage of pain relief was recorded
[27,28]. Both of these did find that less pain relief was required for
patients with fibrin glue [27,28]. Hence, the effect of fibrin glue on pain
after dressing change should be explored further.
The other objective of this study was to determine the relevance to
the skin cancer population, which frequently require grafts.
Unfortunately, there were small numbers of patients with any co-
morbidity studies, and a paucity of skin cancer grafts. It is difficult to
ascertain how relevant these findings may be for this population and
dedicated studies should be conducted.
4.2. Suitable endpoints
One of the major issues with the current literature is the hetero-
geneity of endpoints which have been chosen. This has contributed to
the risk of bias as there may have been selective reporting of endpoints
in studies, for example if haematoma/seroma events were collected but
not reported. It also makes comparisons quite difficult as the outcomes
have not only been measured differently but reported differently across
different studies. For example, one study chose only to look at the effect
of skin grafting on mobility and functional outcomes, but no other
studies examined these endpoints [40]. This heterogeneity in outcomes
may reflect differences in opinions as to which outcomes are important
to measure. However, this makes comparison difficult across any stu-
dies which examine interventions in skin grafting. Our suggestion
would be to establish a pre-determined set of outcomes which reflect
clinical measurements, patient reported measures which reflect sa-
tisfaction and hospital system measures. Of the outcomes discussed in
this paper, graft survival and haematoma/seroma would be clinical;
pain, patient reported satisfaction, length of stay and operating time
would be hospital system measures. There is a paucity of patient sa-
tisfaction related outcomes in the literature, which is important to
consider in skin grafting where the outcomes are immediately apparent.
4.3. Limitations
Bias and the quality of the published literature were limiting factors
in this review. Funding from commercial companies is of concern, al-
though most papers noted that company representatives were not in-
volved in the study design or implementation. Poor randomisation
methods such as lack of allocation concealment also contributed to
issues in many studies. Blinding is difficult with this intervention as it is
immediately apparent to patients and carers as soon as dressings are
removed whether staples or fibrin glue were used. Some studies had
independent assessors or photographic software analysis to attempt to
overcome this [28,36]. Furthermore, early studies were not required to
undergo trial registry and so protocols were not accessible. Authors
were contacted for extra information, but this was not always suc-
cessful. A final limitation is that non-English papers were excluded.
5. Conclusions
While there may be benefits to the use of fibrin glue in skin graft
patients, it is difficult to conclude this from the current evidence. The
papers published focus on many different outcomes, and as a re-
commendation we would suggest some standard outcomes are used in
future skin graft research. In addition, further high quality randomised
controlled trials with large comparison groups are necessary to de-
termine the usefulness of fibrin glue in clinical practice.
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